- Progenics Pharmaceuticals (PGNX +2.4%) completes enrollment in a Phase 2 study of PSMA ADC in metastatic castrate resistant prostate cancer.
- The enrolled patients are chemotherapy experienced.
- The company is also enrolling chemotherapy naive patients in a second cohort.
- Top-line data from the chemotherapy experienced cohort is expected in January. (PR)
From other sites
at CNBC.com (Jul 15, 2014)
at CNBC.com (Jul 14, 2014)
at CNBC.com (Apr 1, 2013)
at CNBC.com (Aug 9, 2012)
at CNBC.com (Aug 8, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs